Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies
Compugen Ltd. - Ordinary Shares (MM) (NASDAQ:CGEN)
Intraday Stock Chart
Today : Monday 5 August 2013
Click Here for more Compugen Ltd. - Ordinary Shares (MM) Charts.
Compugen Ltd. (NASDAQ: CGEN) announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators. Under the terms of the agreement, Bayer HealthCare (Bayer) and Compugen will jointly pursue a preclinical research program. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics.
Under the agreement Compugen will receive an upfront payment of USD 10 million, and is eligible to receive over USD 500 million in potential milestone payments for both programs, not including milestone payments of up to USD 30 million associated with preclinical activities. Additionally, Compugen is also eligible to receive mid to high single digit royalties on global net sales of any resulting products under the collaboration.
“Bayer is committed to translating the science of cancer research into effective therapies helping people affected by cancer live longer and improve their quality of life,” said Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. “Antibody-based immunotherapies are promising approaches in oncology which can stimulate the body’s own immune cells to fight cancer cells. Immunotherapy is one of our focus areas in oncology research. We are looking forward to expanding our portfolio in this area through partnering with Compugen.”
Anat Cohen-Dayag, Ph.D., President and CEO of Compugen, added, “We are very excited to initiate this collaboration with Bayer, a leading global life science company with a broadening oncology franchise, for the development of antibody-based cancer immunotherapies against these two promising novel immune checkpoint targets. In addition, we believe that the prediction and validation of these two targets, through the use of our broadly applicable predictive discovery infrastructure, provides additional validation for our long-term commitment to establishing this unique capability".
The immunotherapy approach aims at combatting cancer by stimulating the body's own immune cells. The tumor and its environment suppress the ability of cancer patients to develop an effective anti-tumor immune response and in this way protect both tumor growth and survival. Compugen has discovered two novel immune checkpoint regulators that potentially play a key role in immunosuppression. Researchers at Compugen are developing specific therapeutic antibodies that are geared to block the immunosuppressive function of these targets and to reactivate the patient's anti-tumor immune response in order to fight cancer.
About Cancer Immunotherapy
Latest cancer immunotherapies have demonstrated impressive clinical benefit, even for end-stage patients with difficult-to-treat tumors such as metastatic melanoma and non-small cell lung cancer. Unlike conventional cancer therapies, which act by directly targeting the cancer cells, resulting often in only transient clinical responses as cancer cells become resistant, clinical responses to cancer immunotherapy tend to be durable, sometimes resulting in dramatic long term survival and absence of resistance or recurrences.
About Compugen
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.
On August 2, 2013 Compugen filed Form-6K with its financial statements for the six months ended June 30, 2013 and will host a public conference call at 10:00 AM ET on Wednesday, August 7, 2013 to discuss these results and any questions with respect to this press release. Further information regarding the conference call is provided in a separate press release issued today and on our website.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which include statements related to the potential development and commercialization of antibody-based cancer immunotherapies against the Compugen-discovered immune checkpoint targets, potential milestone and royalty payments, and that the collaboration validates Compugen’s predictive discovery infrastructure, include words such as “may,” “expects,” “anticipates,” “potential,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks and other factors are discussed in the "Risk Factors" section of Compugen’s Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
7:04AM Compugen discloses focused target discovery program for antibody-drug conjugate cancer therapy (CGEN) 5.26 : Co disclosed the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Co's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody drugs for cancer immunotherapy.
7:56AM Compugen discloses focused target discovery program for antibody-drug conjugate cancer therapy (CGEN) : Co disclosed the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Company's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody drugs for cancer immunotherapy.
Second program follows initial program that resulted in discovery of multiple novel immune checkpoint molecules and establishment of Pipeline Program.
Initial discoveries from new program anticipated before year-end
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy
Today : Tuesday 2 April 2013
Compugen Ltd. (NASDAQ: CGEN) disclosed today the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate (ADC) cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Company's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody (mAb) drugs for cancer immunotherapy.
Cancer therapy through ADCs, whereby the antibody delivers a cytotoxic drug directly and specifically to the cancer cell in order to induce direct killing of the cells, addresses an area of high unmet medical need and is of great interest to the pharma industry. However, the lack of suitable ADC targets is a major problem. This provides an opportunity for Compugen to serve as a key source of such potential targets and their mAbs.
Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, “Concurrent with our further research and development activities and collaboration discussions involving our leading Pipeline Program product candidates, we are pleased to disclose this second focused discovery effort, which was a previously stated objective for 2013. Based on the success of our first such effort, we expect initial ADC target discoveries to be added to our pipeline by yearend, thus further expanding the scope and diversity of the cancer therapy arm of our pipeline.”
The new discovery platform is designed to provide hypothesis-driven analysis of complex sets of expression and clinical data to predict proteins that can serve as novel mAb targets. The platform is based on the integration of multiple proprietary systems, tools, and algorithms from Compugen’s existing predictive discovery infrastructure with additional new specialized algorithms and queries geared towards ADC target discovery. Through the use of this discovery platform, utilizing data from numerous clinically annotated biological samples from various solid cancers, Compugen intends to identify potential high value targets expressed on the surface of various types of cancer cells that are associated with poor clinical outcomes, such as low overall survival and short relapse-free survival. A planned additional use of the discovery platform is the identification of mAb targets associated with tumors unresponsive to certain treatments, thereby potentially providing a more personalized therapeutic approach based on the target's expression level in individual patients.
About ADC Cancer Therapy and Cancer Immunotherapy
ADC cancer therapy destroys cancer cells through the use of an antibody or antibody fragment linked to a high-potency cytotoxic agent, called the payload. Unlike traditional cancer therapeutics, ADC therapy is designed to target and destroy only the cancer cells. The antibody specifically targets the cancer cell, where the payload is released and selectively kills the cancer cell. ADCs against a number of targets, both in solid and hematologic tumors, have already demonstrated clinical success, with two ADC products gaining FDA approval in the past two years.
Cancer immunotherapy, such as that based on immune checkpoint blockade, is designed to stimulate the patient’s own immune system to mount durable anti-tumor immunity and tumor destruction, and does not rely on toxic agents to destroy the cancer. Clinical studies employing mAb blockade of immune checkpoints have shown unprecedented durable therapeutic responses that offer a possible cure of metastatic disease. Antibodies targeting immune checkpoints have been termed “the next frontier" in the treatment of cancer, with the first such product receiving FDA approval in 2011.
ADC cancer therapy and cancer immunotherapy are both considered major breakthroughs in treating cancer, and for both, the identification of appropriate targets is critical and has proven very difficult using traditional discovery approaches.
CGEN $4 "Compugen announces $15 mln funding agreement for its Keddem subsidiary (CGEN) 3.94 : Co announced the signing of an agreement with a private U.S.-based investment company pursuant to which up to $15 mln in milestone related equity financing will be made available to Keddem Bioscience, currently a wholly owned subsidiary of Compugen. This financing will be used to further develop and commercialize a unique technology platform that has been designed to consistently enable the discovery of small molecule modulators for potentially any given protein target. Under the agreement, the new investor will obtain a majority equity interest in Keddem, with Compugen maintaining a minority interest and certain future preferential access rights to utilize the Keddem technology with Compugen discovered drug targets." BRIEFING
8:21AM Compugen announces discovery of two novel immune checkpoint targets for cancer immunotherapy (CGEN) 3.72 : Co announced the discovery and initial validation of two new drug target candidates for monoclonal antibody (mAb) cancer therapy. These new candidates have been shown to be expressed in multiple types of tumors and were shown to have an immunomodulatory activity in affecting both innate and adaptive immune responses, thus providing the potential for an efficient and targeted approach in cancer treatment.
By offering a different mode of action from Compugen's other immune checkpoint candidates, these molecules further broaden the scope of the Company's Pipeline Program for monoclonal antibody treatment of cancer. In recent in vitro studies, both of these immune checkpoint molecules have shown distinct activity inhibiting two key subtypes of immune cells, Natural Killer (NK) cells and T cells. These key immune cell subtypes act to recognize and kill tumor cells and have critical roles in the response of the immune system to tumor development.
10:25AM Compugen postpones issuance of third quarter 2012 report and associated conference call to November 5 due to expected severe weather conditions (CGEN) 3.72 : The issuance of the report and the call were previously planned for Tuesday, October 30, 2012 at 10 a.m. ET.
Compugen's CEO Discusses Q2 2012 Results - Earnings Call Transcript
http://seekingalpha.com/article/787691-compugen-s-ceo-discusses-q2-2012-results-earnings-call-transcript?source=yahoo
Compugen and Merck Serono Ventures to Jointly Establish New Biomarker Company Neviah Genomics Ltd.
Today : Monday 25 June 2012
Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen Ltd. (NASDAQ: CGEN) today announced the establishment of Neviah Genomics, a novel start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will be operating out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the initial funding for Neviah Genomics. Compugen will utilize certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales. Further financial details of the agreement were not disclosed.
Neviah Genomics represents the first investment within the framework of the recently formed Merck Serono Israel Bioincubator program. As such, Neviah Genomics will operate out of the state-of-the-art facilities inaugurated last month at Merck Serono’s Israeli R&D center Inter-Lab, which offers 600 square meters of infrastructure and a wide range of incubation services for the program's new start-ups.
This agreement follows a successful collaboration between Merck Serono and Compugen for the discovery of "biomarker signatures" for drug induced toxicity during 2009. Merck Serono and Compugen believe that establishment of Neviah Genomics with the combined capabilities of the two companies could satisfy the growing market need for products to predict toxicity profiles of lead drug candidates at an early stage of development, thereby minimizing attrition and mitigating risk of late-stage drug failure.
Anat Cohen-Dayag, Ph.D., President and CEO of Compugen said, “Following our prior successful collaboration with Merck Serono, we are very pleased to expand this relationship and enter into this new and exciting partnership. We are honored to be the first Israeli company to benefit from the establishment of Merck Serono's Israel Bioincubator and look forward to taking our partnership to the next level.” Dr. Cohen-Dayag continued, “Furthermore, the formation of Neviah Genomics on a 'discovery on demand' basis enables Compugen to both continue its focus on therapeutic monoclonal antibodies and therapeutic proteins in the fields of immunology and oncology, and provide potential future benefits for our shareholders from our equity interest in Neviah and royalties from future product sales.”
“Neviah Genomics is a perfect illustration of our goals behind the establishment of the Israel Biotech Incubator: to leverage Israeli science and know-how and get access to novel products and technologies for the benefit of Merck Serono’s core therapeutic areas,” said Susan Herbert, Executive Vice President, Global Business Development and Strategy at Merck Serono. “In this regard, we are delighted to be collaborating on our first investment with Compugen, one of the premier biotech companies in Israel and a world leading predictive drug discovery company. We believe that our joint technology and resources represent a unique basis for a start-up to enter this emerging field that has the potential to significantly reduce the risk of drug discovery and development.”
Neviah Genomics will benefit from Compugen's sophisticated proprietary computational discovery platforms to develop advanced toxicogenomics diagnostic tests. Developed tests will be used for the prediction of drug-induced toxicity and integrated into a biomarker platform to support the prioritization and development of drug product candidates.
Total Cash (mrq): 24.99M
Total Cash Per Share (mrq): 0.71
Total Debt (mrq): 0.00
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 12.28
Book Value Per Share (mrq): 0.60
Avg Vol (3 month)3: 114,581
Avg Vol (10 day)3: 104,038
Shares Outstanding5: 35.29M
Float: 33.47M
% Held by Insiders1: 10.04%
% Held by Institutions1: 18.20%
Shares Short (as of May 31, 2012)3: 482.40K
Short Ratio (as of May 31, 2012)3: 3.40
Short % of Float (as of May 31, 2012)3: 1.50%
Shares Short (prior month)3: 485.54K
JOKE STOCK. no revenues.
7:19AM On The Wires (WIRES) : Compugen (CGEN) announced the establishment of operations in South San Francisco, California for the development of oncology and immunology monoclonal antibody drug candidates against Compugen-discovered targets. Drug candidates to be developed against Compugen-discovered targets .
That would make perfect sense. I know a lot of money is being pumped into the market though.. Crazy times ahead imo.
Yep its posted:
Zero revenues in the 4th quarter and the net loss for the 4th quarter was $4.4 million.
Might pull back slightly imo.
~ $CGEN ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $CGEN ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=CGEN&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=CGEN&p=W&b=3&g=0&id=p54550695994
~ Barchart: http://barchart.com/quotes/stocks/CGEN?
~ OTC Markets: http://www.otcmarkets.com/stock/CGEN/company-info
~ Google Finance: http://www.google.com/finance?q=CGEN
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CGEN#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CGEN+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CGEN
Finviz: http://finviz.com/quote.ashx?t=CGEN
~ BusyStock: http://busystock.com/i.php?s=CGEN&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=CGEN&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=CGEN
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=CGEN
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=CGEN
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=CGEN
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=CGEN
~ MarketWatch: http://www.marketwatch.com/investing/stock/CGEN/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=CGEN
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CGEN
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CGEN&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CGEN&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CGEN&size=l&frequency=60&color=g
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
6:01AM Compugen announces results showing its CGEN-15001T drug may have potential for cancer immunotherapy (CGEN) 5.30 : Co announced results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody ("mAb") therapy. These results indicate that CGEN-15001T is expressed on numerous types of cancer, such as carcinomas, sarcomas, melanoma and hematological cancers as well as on immune cells. These findings, together with previous results supporting its active immunomodulatory effect, 'strongly support CGEN-15001T's potential as a powerful drug target for treatment of various solid and hematological cancers, an area of great interest to the pharmaceutical industry.'
Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology
$8 million towards expanded program will be provided by Baize Investments via second research funding agreement with Compugen
Business WirePress Release: Compugen Ltd. – Tue, Dec 20, 2011 10:30 AM EST
TEL AVIV, Israel--(BUSINESS WIRE)-- Compugen Ltd. (NASDAQ: CGEN - News) announced today that it will significantly broaden and accelerate its monoclonal antibody (mAb) activities for oncology and immunology within its ongoing Pipeline Program. The expanded activities will include a significant increase in the number of mAb candidates being developed in parallel against Compugen-discovered targets in the Pipeline Program, and the planned in-house establishment of certain key mAb preclinical development capabilities that were previously intended to be obtained solely from third parties.
The Company also announced that $8,000,000 towards the expanded program will be provided to the Company under a research funding agreement signed today with Baize Investments (Israel) Ltd. (“Baize“), a private corporation investing in innovative medical technologies. This follows an earlier research funding agreement between the two parties in December 2010, pursuant to which Compugen received $5,000,000 in support of the initiation of the Pipeline Program.
Under the terms of the new agreement, in exchange for its $8,000,000 in funding, Baize will receive a financial interest in certain mAb product candidates that achieve a specified development milestone, or have been licensed out, during the next three years. In addition, Baize has the right, during the first quarter of 2014, to waive its rights to all future benefits from this financial interest in exchange for 1,455,000 Compugen ordinary shares.
Dr. Anat Cohen-Dayag, President and CEO of Compugen, stated, “During the last two years we were pleased to disclose successful validation of a number of our Pipeline Program therapeutic proteins, such as CGEN-15001 and CGEN-15091, in animal models of autoimmune diseases. This progress continues as we concurrently discuss potential arrangements for further product development and commercialization under royalty bearing licenses and other forms of collaboration. With respect to antibody therapeutics for oncology and immunology, the other focus area of our Pipeline Program, our competitive advantage rests on our unique predictive capabilities to discover novel molecular targets for the subsequent development of monoclonal antibodies that serve as the actual drug product candidates. This is in contrast to the discovery of therapeutic proteins, where our predictive capabilities lead directly to the proteins that serve as the basis for product development.”
Dr. Cohen-Dayag continued, “mAbs are the most rapidly growing drug class, with over 20 mAbs already approved for therapeutic use in the U.S. and in addition have demonstrated a higher success rate in development than other drug classes. However, a key continuing challenge is the identification of novel promising targets. To this end, Compugen harnessed its unique predictive capabilities to develop target discovery platforms and now has a growing inventory of promising potential mAb targets in validation. A number of these targets are now approaching the point where further advancement will require the development of mAbs against them.”
Dr. Cohen-Dayag concluded, “Based on our successful in silico prediction and selection of potential mAb target molecules, we are very pleased to be announcing today a significant broadening and acceleration of our mAb therapeutics program, including an increase in the number of targets against which we will concurrently develop mAbs to be advanced to the preclinical stage prior to out-licensing. Furthermore, since our expectation is that we will have an ongoing need to create and develop mAbs as we continue discovering new targets, we believe it is in our best interest to establish an in-house capability for further mAb development activities. This in-house capability would be in addition to reliance on third parties under arrangements that would normally include sharing of future profits from the resulting mAb product candidates.”
Murray Goldman, Baize’s Chairman, stated, “We are pleased with the progress achieved by Compugen with respect to its Pipeline Program in general and the specific product candidates in which we have a financial interest, and we are proud to have been of assistance in the Program’s initiation in late 2010. Therefore, we are now very much looking forward to expanding this relationship by focusing on accelerating the development in parallel within the Pipeline Program of mAbs against a number of promising Compugen discovered targets in oncology. This is anticipated to lead to significant new therapeutic candidates addressing key unmet needs in cancer treatment, which could meaningfully contribute to the well-being of humanity.”
Mr. Martin Gerstel, Chairman of the Board of Compugen, added, “After more than a decade of building the required predictive discovery infrastructure and scientific foundation, during the past few years we have made three critical decisions pertaining to the potential medical and financial opportunities now available to us due to these successful past and ongoing investments. First, we decided to focus our efforts on monoclonal antibodies and therapeutic proteins in the fields of oncology and immunology. Second, our powerful discovery infrastructure enabled us to quickly establish a Pipeline Program of approximately 30 promising early stage candidates. And finally, our continued target discovery success in the mAb arm of our Pipeline Program has now led us to a third decision: to substantially broaden and accelerate this portion of our Pipeline Program to obtain the maximum value from our target discoveries.”
Mr. Gerstel concluded, “A major partner for Compugen in implementing these decisions has been Baize Investments. Our first Research Funding Agreement with Baize, signed in 2010, allowed us to aggressively initiate the Pipeline Program, without exposing our company to increased financial risk in a difficult economic environment, and without significantly diluting the interests of our existing shareholders base that had in large part provided the resources to allow us to create these opportunities. And now, once again, this new agreement with Baize will allow us to significantly broaden and accelerate the advancement of our extremely promising mAb activities within the Pipeline Program, while again protecting the interests of our current shareholders.”
The New Funding Agreement with Baize Investments
In exchange for $8,000,000 in research funding, Baize will receive a financial interest in therapeutic mAb product candidates to be developed against 12 specified Compugen-discovered targets in the field of oncology, provided that any such mAb product candidates either achieves a successful animal disease model during the next three years, and/or is licensed out to third parties for final development and commercialization during such time period. In each such case, Baize’s financial interest in such qualifying mAb product candidate will consist of the right to receive from Compugen a percentage of certain future payments received by Compugen from third parties from any out-licensing for further development and/or commercialization. The percentage for each such qualifying mAb product candidate will be calculated on the date of out-licensing in accordance with a sliding scale, which takes into account the total Baize research funding spent for the development of therapeutic mAbs against the specified 12 Compugen targets to such date, relative to the total amount invested by both Baize and Compugen in such mAbs, provided that Baize will be entitled to no less than ten percent of such future payments related to any qualifying mAb product candidates. In addition, Baize has the right, during the first quarter of 2014, to waive its rights to receive all such future payments in exchange for 1,455,000 Compugen ordinary shares.
About mAb Therapy
Monoclonal antibody (mAb) therapy is a class of biological drugs that bind with high specificity to target cells or proteins. Due to the versatility and specificity of this approach, mAb therapies are being intensively researched and developed as treatments for numerous serious diseases with the expectation of higher efficacy and fewer side effects compared to traditional chemical drugs. For cancer therapy, a mAb may inhibit cellular processes critical for tumor growth, stimulate the patient's immune system to attack the target cancerous cells, or be used for targeted delivery of chemotherapy specifically to the cells identified by the antibodies. DataMonitor estimated the global monoclonal antibodies market to reach $65 billion by 2016. Moreover, according to an analysis done by Tufts University the rate of success for mAb therapeutics from first use in humans to regulatory approval is more than double that of traditional chemical drugs.
7:03AM Compugen CGEN-15001 pre-clinical data presented at International Conference on immune tolerance (CGEN) 4.19 : Co announced that CGEN-15001 was the subject of a presentation by Joseph Podojil, Ph.D. of the Feinberg School of Medicine Northwestern University, at the 2nd International Conference on Immune Tolerance, now being held in Amsterdam. This is the first time that scientific information related to CGEN-15001's therapeutic potential is being presented to the scientific community. In his talk, Dr. Podojil presented data demonstrating that administration of CGEN-15001 in the experimental autoimmune encephalitis (EAE) animal model of multiple sclerosis (MS) resulted in a dramatic improvement of disease symptoms and abolishment of spontaneous relapses. In addition, the study results demonstrated that short-term treatment with CGEN-15001 lead to long-term inhibition of disease symptoms as well as of the underlying spread of pathological immune responses.
8:07AM Compugen announces the Pulmonary Fibrosis Foundation to fund further therapeutic evaluation studies for Compugen-discovered drug candidate (CGEN) 4.16 : The co and the Pulmonary Fibrosis Foundation announced that the Pulmonary Fibrosis Foundation will provide a grant to scientists to independently evaluate the therapeutic potential of CGEN-25009 for the treatment of idiopathic pulmonary fibrosis. The experiments are designed to further establish the anti-fibrotic properties of CGEN-25009 in multiple animal models of fibrosis, to elucidate the mechanism of CGEN-25009's anti-fibrotic effects, and to prioritize potential biomarkers for the study of CGEN-25009 in patients with idiopathic pulmonary fibrosis... Co says that "although our primary business development efforts are directed towards our oncology and immunology Pipeline Program and 'discovery on demand' activities, we are now in various discussions for arrangements with other organizations to advance certain of these earlier discoveries, including a number of promising novel peptides, largely without the need for further Compugen financial resources, such as the collaboration being announced today."
Compugen Announces Validation of Two Immune System Modulating Drug Candidates
Novel immunomodulatory proteins demonstrate significant therapeutic potential for autoimmune diseases
New drug candidates based on two B7/CD28-like proteins discovered through use of Compugen’s Protein Family Members Discovery Platform
Press Release Source: Compugen Ltd. On Tuesday September 13, 2011, 7:00 am EDT
TEL AVIV, Israel & NEW YORK--(BUSINESS WIRE)-- Speaking today at the Rodman & Renshaw Annual Global Investment Conference in New York City, Martin Gerstel, chairman of Compugen Ltd. (NASDAQ:CGEN - News), reviewed the current status of the Company and announced the validation of two therapeutic product candidates, CGEN-15021 and CGEN-15091, in various autoimmune disease animal models. These two molecules are soluble proteins based on two B7/CD28-like proteins recently discovered by Compugen. In view of its key role in modulating immune response, the B7/CD28 family of proteins is of high interest in medical research and to the pharmaceutical industry, and these newly discovered molecules share key characteristics with this protein family. In addition to the potential use of CGEN-15021 and CGEN-15091 as protein therapeutics for multiple autoimmune diseases, the two proteins they are based on are predicted to have utility as drug targets for monoclonal antibody therapy in oncology.
CGEN-15021 and CGEN-15091 are both soluble fusion proteins, each combining the extracellular domain of one of the newly discovered B7/CD28-like proteins and an Fc antibody fragment. Fusion to an Fc antibody fragment is an established methodology to create soluble long-acting therapeutic proteins. The results being announced today relate to the recent validation of CGEN-15021 in animal disease models of both multiple sclerosis and rheumatoid arthritis, and of CGEN-15091 in an animal disease model of multiple sclerosis. In each of these disease models, the Compugen fusion proteins demonstrated dramatic therapeutic effects in ameliorating disease symptoms. In addition, in earlier in vitro experiments, CGEN-15021 and CGEN-15091 exhibited inhibition of T cell activation, confirming their predicted role in the modulation of the immune system.
In his presentation (which has been posted on Compugen’s website: www.cgen.com), Mr. Gerstel stated, “The discovery process for these two immunomodulatory proteins is an excellent example of the power and uniqueness of the broad based scientific infrastructure for predictive discovery that has been established at Compugen over the past decade. This infrastructure now allows the rapid development of accurate in silico capabilities for the prediction of innovative therapeutic solutions in selected areas of unmet medical need. In this case, we initially directed these capabilities to the B7/CD28 protein family, a protein family of very high industry interest due to its key role in regulating immune responses, and one with significant therapeutic potential in major pathological conditions, such as autoimmune diseases, transplantation and cancer.”
Mr. Gerstel continued, “Within approximately six months, we had integrated multiple components of our infrastructure capabilities to develop the Protein Family Members Discovery Platform, which during its initial discovery process, predicted nine new proteins sharing characteristics with the B7/CD28 protein family. The first three of these nine, consisting of the previously disclosed CGEN-15001 which is currently moving forward in our Pipeline Program, and the two proteins for which positive in vivo results are being announced today, have now been validated in established animal disease models. In addition, we subsequently extended this discovery capability beyond the B7/CD28 family, as well as developing additional capabilities for the discovery of other types of immune related proteins, some of which are now beginning the validation process.”
Mr. Gerstel continued, “With respect to today’s disclosure, the in vitro validation experiments and the in vivo study in a multiple sclerosis animal model of CGEN-15021 and CGEN-15091 were part of Compugen’s long-term research agreement with Prof. Stephen Miller’s laboratory at Northwestern University. The in vivo validation of CGEN-15021 in a rheumatoid arthritis model was conducted at Dr. Richard Williams’ laboratory at the Kennedy Institute of Rheumatology, Oxford University. Having long-term relationships with leading scientists at academic laboratories with well established assays and animal models, enables Compugen to quickly and efficiently validate its new discoveries.”
Mr. Gerstel concluded, “We enthusiastically look forward to the further development of these very attractive drug candidates, and to the ongoing application of our unique capabilities to additional areas of unmet medical need.”
About the B7/CD28 Protein Family of positive and negative co-stimulatory proteins
Members of the B7/CD28 families have been intensively studied over the past decade and have brought much excitement to the field of immune regulation. The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor with an antigenic peptide-MHC complex. The outcome of this engagement is determined by both positive and negative co-stimulatory signals, generated mainly by the interaction between members of the B7 family ligands and their receptors, members of the CD28 family. A growing body of evidence indicates that the dysfunction of immune regulation contributes to the development of autoimmune diseases.
Positive and negative co-stimulatory pathways play critical roles in immune regulation and are considered potential targets for modulating chronic inflammation in autoimmune diseases. To date, one soluble recombinant fusion protein that selectively blocks the co-stimulatory signal mediated by the prototype B7/CD28 pathway has been cleared for marketing in the U.S. for the treatment of moderate to severe rheumatoid arthritis, and is in clinical trials for other autoimmune indications. In addition, a number of clinical and preclinical studies for therapeutic agents targeting these protein families are underway at various companies.
CGEN seems to be setting up to break through some downward trend lines in the coming days & should be moving higher...
8:06AM Compugen announces initial validation of additional B7/CD28 protein family based product candidate (CGEN) 3.77 : Co announced in vitro validation of a second product candidate based on Compugen-discovered novel members of the B7/CD28 co-stimulatory protein family. Proteins belonging to the B7/CD28 family are of high industry interest in view of their key roles in regulating immune response and are viewed as having significant therapeutic potential in multiple areas of important medical need, including autoimmune diseases, transplantation and cancer.
7:09AM On The Wires (WIRES) :
Compugen (CGEN) announced the development of a method to identify novel therapeutic candidates to interfere with disease associated protein conformations and protein-protein interactions.
Compugen Discloses Splice Variant Based Program to Discover Superior Oncology Drug Targets for mAb Therapy
To date four protein splice variants have been identified and predicted to have potential advantages as oncology targets compared with the known proteins
Other Compugen target discovery programs are based on new members of protein families, expression analysis and functionality prediction
Press Release Source: Compugen Ltd. On Wednesday April 27, 2011, 7:00 am EDT
TEL AVIV, Israel--(BUSINESS WIRE)-- Compugen Ltd. (NASDAQ:CGEN - News) announced today that it is utilizing its proprietary in silico human transcriptome and proteome and additional computational systems to discover splice variants of known drug targets of high industry interest and of other known proteins with potential to become cancer targets for mAb therapy. This program has resulted so far in the discovery of four novel splice variant proteins predicted to be superior oncology targets compared with the previously known proteins. These four splice variants have entered Compugen’s Pipeline Program and are at various stages of validation.
Compugen’s proprietary in silico transcriptome and proteome infrastructure is the result of its decade-long research and modeling of various biological phenomena, including alternative splicing, resulting in a rich, comprehensive, and broadly applicable discovery infrastructure consisting of all genes and their respective splice variants and resulting proteins. In this program, Compugen is utilizing this proprietary knowledge database, together with additional discovery systems and tools, to discover novel splice variants that can serve as superior mAb targets.
Dr. Zurit Levine, Compugen’s VP of R&D, stated, “We first selected a list of known proteins and drug targets that meet industry therapeutic criteria. Challenging traditional experimental discovery methods, we then utilized our in silico predictive human transcriptome and proteome, and additional proprietary discovery tools, to systematically discover previously unknown splice variants, which, although expressed by the same genes as the known proteins, have a unique epitope within their extracellular region which would allow the development of specific mAbs. Next, we tested their predicted expression, function and certain other properties compared with the known proteins. For example, several of these candidate targets exhibited a potential unique expression pattern, while others exhibited a potential superiority in their functional or structural characteristics. To date, this process has resulted in four candidate targets with predicted superiority compared with the existing proteins.”
Dr. Levine continued, “Including this splice variant program, we are now discovering potential targets for monoclonal antibodies and other therapeutic approaches through the use of four distinct but mutually supporting programs. The other three target discovery programs are based on sophisticated expression analysis utilizing our unique MED Platform and its new field extension modules, new protein family members, and, at an earlier stage of capability development, functional prediction. With respect to mAb therapy, these four approaches facilitate discovery of candidate targets applicable for various mAb technologies, such as antibody-drug conjugates (ADCs), and enhanced antibody dependent cell mediated cytotoxicity (enhanced ADCC).”
Dr. Anat Cohen-Dayag, president & CEO of Compugen, added, “This is an excellent example of how we can utilize our proprietary predictive biology infrastructure on a ‘market-need’ driven basis to quickly identify in silico discoveries in areas of high industry interest that have eluded traditional experimentally based approaches. It took more than a decade of pioneering the understanding of key life processes at the molecular level, such as alternative splicing, to create the core of this infrastructure, but it is now proving to be a valuable and unique resource for systematic therapeutic and diagnostic product candidate discovery.”
About Alternative Splicing
mRNA transcripts are produced from the genome by a process of transcription and splicing, in which the exons of the gene are derived from the genome and connected to create the resulting transcript. Alternative splicing is a phenomena that occurs when various different exon combinations are possible, thus resulting in multiple mRNA transcripts originating from the same gene. These different mRNA transcripts are translated into multiple possible protein isoforms which may have similar or different functions. The combinatorial nature of alternative splicing enables the genome to produce numerous transcripts from a relatively small number of genes, allowing a more varied proteome.
For more than a decade, Compugen has been a pioneer and continues to be a world leader in understanding the alternative splicing of genes and predicting the resulting combination of exons leading to the formation of splice variants that are probable to occur in nature. One of Compugen’s first breakthroughs in the deeper understanding of biological phenomena at the molecular level was its prediction regarding the high prevalence of alternative splicing. This prediction, that alternative splicing is the norm rather than the exception, was later confirmed by the Human Genome Project and following works, which resulted in the understanding that fewer genes exist in the human genome than previously believed.
Compugen Reports First Quarter 2011 Financial Results
Corporate Overview and Status to be Presented in Webcast Today at 10 AM EDT
Press Release Source: Compugen Ltd. On Wednesday May 11, 2011, 7:45 am EDT
TEL AVIV, Israel--(BUSINESS WIRE)-- Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the first quarter ending March 31, 2011.
Dr. Anat Cohen-Dayag, president and CEO, stated, "Compugen continues to advance its Pipeline Program, targeting the development of superior therapeutic products for important unmet medical needs. As previously disclosed, although our underlying predictive discovery infrastructure is broadly applicable for biological therapeutics and molecular diagnostics, our current focus is on monoclonal antibody ("mAb"), protein and peptide therapeutics in the fields of oncology and immunology, including both autoimmune and inflammatory conditions. Currently, there are more than 30 candidates at various stages of evaluation. In addition to our efforts in advancing this early stage therapeutic pipeline, we continue to undertake additional candidate discovery programs to both increase the number of candidates in the Pipeline and replace those that fail. And, to maintain our leadership position in predictive discovery, our research team continues to enhance our unique discovery infrastructure through the development of additional algorithms and platforms."
Martin Gerstel, Compugen’s chairman, added, "As exemplified in our recent press release describing our broad capabilities in the discovery of superior targets for mAb therapy in cancer, and as illustrated by our existing Pipeline Program to be reviewed in today's webcast, we are finding that the ability to systematically address unmet medical needs through the combined utilization of a number of distinct, but mutually supporting methodologies, all of which are predictive based, is proving to be a major competitive advantage for our Company."
As previously stated, our quarterly results are, and will continue to be, subject to substantial fluctuations. No revenues were recorded for the first quarter of 2011 compared with $125,000 for the first quarter of 2010.
The net loss for the most recent quarter was $1.9 million (including a non-cash expense of $379,000 related to stock based compensation), or $0.06 per share, compared with a net loss of $2.7 million (including a non-cash expense of $911,000 related to stock based compensation), or $0.08 per share, for the corresponding quarter of 2010.
Research and development expenses were $1.7 million for the first quarter of 2011 and $1.6 million for the first quarter of 2010 and remain the Company’s largest category of expense. The amount for the first quarter of 2011 is before the deduction of $48,000 of governmental and other grants; no grants were recognized for the first quarter of 2010.
As of March 31, 2011, Compugen had $25.5 million in cash and cash equivalents and short-term bank deposits, compared with $21.8 million as of December 31, 2010. These amounts do not include the market value of the Evogene shares held by the Company.
Conference Call and Webcast Information
The Company will host a live webcast and conference call at 10:00 AM EDT on Wednesday, May 11, 2011 to review first quarter 2011 results and to present a corporate overview and status slide presentation focusing on the Company’s Pipeline Program.
The live webcast can be accessed from Compugen’s website (www.cgen.com) or at this link. The audio portion will also be available via conference call, which can be accessed by dialing 1-888-407-2553 from the US, or +972-3-918-0610 internationally.
The presentation slides will be available under corporate presentations on the financial reports page of the investors section of the Compugen website (www.cgen.com) or at this link. After clicking on the link, please enter your information, and then please select the second option "Web Participant Application". For support, please call +972-3-925-6000.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-295-2634 from the US or +972-3-925-5928 internationally. The replay will be available through May 14, 2011.
7:04AM Compugen discloses splice variant based program to discover superior oncology drug targets for mAb therapy (CGEN) 4.79 : Co announces that it is utilizing its proprietary in silico human transcriptome and proteome and additional computational systems to discover splice variants of known drug targets of high industry interest and of other known proteins with potential to become cancer targets for mAb therapy. This program has resulted so far in the discovery of four novel splice variant proteins predicted to be superior oncology targets compared with the previously known proteins. These four splice variants have entered Compugen's Pipeline Program and are at various stages of validation.
7:04AM Compugen announces positive animal model results for novel peptide predicted to block protein-protein interaction (CGEN) 5.12 : Co announces positive animal model results for CGEN-25068, a novel peptide predicted and selected in silico to block a specific protein-protein interaction known to play an important role in various immune-related disease conditions. CGEN-25068 is one of a number of novel peptides predicted and selected as part of the validation activities for co's Protein-Protein Interaction Blockers Discovery Platform and is the first of these peptides to complete animal model testing. Additional peptides predicted to block targeted interactions in other pathways, primarily cancer-related, are at various stages of validation.
7:00AM Compugen signs $5 million R&D funding agreement in support of its pipeline program (CGEN) 4.80 : Co entered into an agreement with Baize Investments (Israel), under which it will receive $5,000,000 in R&D funding. Under the terms of the funding agreement, which is in support of Compugen's recently announced Pipeline Program, Baize Investments has obtained a financial interest in five designated Compugen-discovered molecules and has been issued a warrant to purchase 500,000 Compugen shares at an exercise price of $6.00 per share, expiring June 30, 2013.
Compugen Signs $5 Million R&D Funding Agreement in Support of its Pipeline Program
Compugen Ltd. (MM) (NASDAQ:CGEN)
Today : Thursday 30 December 2010
Compugen Ltd. (NASDAQ: CGEN) announced today that it has entered into an agreement with Baize Investments (Israel) Ltd., a private corporation investing, inter alia, in innovative medical technologies, under which it will receive $5,000,000 in R&D funding. Under the terms of the funding agreement, which is in support of Compugen's recently announced Pipeline Program, Baize Investments has obtained a financial interest in five designated Compugen-discovered molecules and has been issued a warrant to purchase 500,000 Compugen shares at an exercise price of $6.00 per share, expiring June 30, 2013.
Baize Investments' financial interest in the five designated molecules consists of the right to receive from Compugen up to 10% of certain future payments received by Compugen from third parties in the event of the successful licensing out for development and/or commercialization of such designated Compugen molecules. Currently, all five molecules are in active research in the Company's Pipeline Program, with their current status ranging from in silico selection to post animal model validation. In addition, the investor has the right, until June 30, 2013, to waive his right to receive all such future payments in exchange for 833,334 Compugen ordinary shares. The financial terms for the investor were established based on the assumption that any out-licensing of the designated molecules would be undertaken no later than IND filing.
Martin Gerstel, Compugen's Chairman, stated, "This arrangement is an excellent example of how we can financially leverage our unique predictive product candidate discovery infrastructure to provide an increasing number of novel and attractive product candidates for potential licensing. Given the continuous expansion and improvement of this infrastructure, the in silico prediction and selection of candidates is from a practical standpoint, essentially without limit as to the number of attractive candidates that can feed our Pipeline Program, and on an extremely cost-effective and systematic basis. Recently we announced the addition of twenty such novel molecules to the Program, and more have been added since that announcement. The funds received by Compugen pursuant to the agreement being announced today will allow us to pursue more aggressively our ambitious objectives for the Pipeline Program during the next few years."
Mr. Gerstel continued, "In view of their long-term interest in the activities of the Company, we are very pleased to have Baize Investments and Mr. Murray Goldman join the Compugen team in this very meaningful endeavor."
Murray Goldman, Baize Investments' Chairman, stated, "During the past few years, we have followed Compugen's scientific progress and growing predictive discovery capabilities. We are extremely pleased to become a financial partner in advancing these exciting product candidates, all of which have the potential to address significant unmet medical needs."
Obvious Drive on news...
http://ih.advfn.com/p.php?pid=nmona&article=45642486
more to come, sure of it...the pipeline looks long
;)
Compugen Ltd. (NASDAQ: CGEN) announced today that it has signed a research collaboration agreement with Seattle Genetics, Inc., USA, covering a Compugen-discovered oncology target. The agreement provides Seattle Genetics with an initial evaluation period and an option for an exclusive worldwide milestone and royalty bearing license for development and commercialization of monoclonal antibody therapeutics addressing this novel target. The existence of the target, which is a previously unknown splice variant of a known oncology target, was initially predicted in silico through the use of Compugen’s Monoclonal Antibody (mAb) Targets Discovery Platform. The predicted molecule’s existence and overexpression in several of the most prevalent solid cancers was recently demonstrated in independent experimentally based studies.
Dr. Anat Cohen-Dayag, president & CEO of Compugen, stated, “We are very enthusiastic about this new collaboration, our first with Seattle Genetics, a leading company in the rapidly growing field of monoclonal antibodies and antibody drug conjugates. The Compugen novel target that is the subject of this agreement has shown potential in a number of important unmet areas of cancer treatment.”
Dr. Cohen-Dayag continued, “We also are pleased to see the continuing and growing interest of the industry with respect to our mAb Targets Discovery Platform. This unique capability, which addresses the key unmet market need in the rapidly growing antibody therapeutic field, is now serving as both the source of targets for collaborations, such as the one being announced today and our ongoing collaboration with Bayer Schering Pharma, and also to predict and select, in combination with other Compugen tools and capabilities, an inventory of potential targets for further internal development under the new program disclosed earlier this week in our quarterly press release.”
Martin Gerstel, Compugen’s chairman, added, “As described in the quarterly release, our business model provides three potential pathways for development and commercialization of our product candidate discoveries. Collaborations can be entered into before our prediction and selection of candidates is undertaken pursuant to ‘discovery on demand’ agreements, or with respect to existing Compugen product candidates, collaborations can be initiated prior to or at the proof of concept stage, or after additional preclinical activities have been undertaken by us. In all cases these agreements provide Compugen with potential milestone payments and royalties on product sales or other revenue sharing arrangements. The decision as to which pathway we choose in each specific case will depend on many factors, such as proprietary knowledge or technology of a potential partner that could expedite and increase the probability of success of development or commercialization; the anticipated overall relationship with the potential partner; our assessment of the risk/reward profile of further development by us; and available financial terms at each point in time.”
About Compugen’s Monoclonal Antibody (mAb) Targets Discovery Platform
Compugen’s mAb Targets Discovery Platform relies heavily on Compugen’s LEADS and MED capabilities, two computational biology infrastructure platforms that serve as core components for the development of Compugen’s discovery platforms. The LEADS platform provides a comprehensive view of the human transcriptome, proteome, and peptidome and serves as a rich infrastructure for the discovery of novel genes, transcripts and proteins. It includes extensive gene information and annotation, such as: splice variants, antisense genes, SNPs, novel genes, RNA editing, etc. At the protein level, LEADS provides full protein annotation, including homologies, domain information, subcellular localization, peptide prediction, and novelty status. The MED Platform is an integrated database composed of the results from more than 40,000 public and proprietary microarray experiments, normalized and organized into approximately 1,400 therapeutically relevant conditions (i.e. normal tissues, malignant tissues, tissues from drug treated patients, etc.). Utilizing a sophisticated query interface, the proprietary MED platform allows the simultaneous examination of the expression of genes and pathways across all 1,400 conditions and tissues as well as all 40,000 microarray experiments.
In addition to incorporating MED and LEADS, the mAb Targets Discovery Platform utilizes multiple data sources and algorithms to predict a large number of novel membrane proteins that can serve as targets for antibody therapeutics, such as for various cancers and autoimmune diseases. The selection of appropriate candidates from this large body of predicted membrane proteins is accomplished using sub-modules of algorithms and other computational tools developed specifically for each disease state or protein family.
Compugen Goes the Extra Mile in Drug Discovery
http://seekingalpha.com/article/220374-compugen-goes-the-extra-mile-in-drug-discovery?source=yahoo
Compugen Reports Second Quarter 2010 Financial Results
http://finance.yahoo.com/news/Compugen-Reports-Second-bw-1813748666.html?x=0&.v=1
Compugen Discovered Protein Shown to Abolish Recurring Relapses in Multiple Sclerosis Animal Model
http://finance.yahoo.com/news/Compugen-Discovered-Protein-bw-3902315198.html?x=0&.v=1
CGEN
Technology Award-Compugen Recognized by York Technology Association as Company of the Year 2010 YTA Technology Leadership Award Granted for Demonstrated Innovation and Leadership in the Field and for Contributions Towards Developing the Technology Commun
TORONTO, ONTARIO, Jun 17, 2010 (MARKETWIRE via COMTEX News Network) --
Compugen Inc. is pleased to announce that it has been named Company of the Year by the York Technology Association (YTA), a membership organization that fosters collaboration and communication amongst technology-driven businesses in York Region and in the Greater Toronto Area. The technology award, one of three being presented at the YTA's First Annual YTA Technology Leadership Awards luncheon on 17 June, recognizes the leadership position Compugen has as a national IT solution provider based in the Region.
Compugen's founder, CEO and President, Harry Zarek, said, "It is critical to the success of any organization to understand its competition, to find a place for itself within the competitive landscape and to capture and maintain the loyalty and respect of its customers. These tasks are impossible without a spirit of collaboration with long-term business partners, customers and an ecosystem of businesses who can deliver for you when you need them. The York Technology Association's aim of bringing together established players and start-ups of all sizes to shorten the time to market of quality technology solutions is one I'm delighted to support. The critical mass of intellectual capital, investors, and experience within the Region and the GTA make this corridor the most exciting place in Canada to mine for ideas, feedback and opportunities for growth. It's the place to be to turn good ideas into great investments and lasting solutions."
About Compugen
Compugen is Canada's largest privately owned IT solution provider providing a comprehensive portfolio of sales and support services across Canada. Still operating under the guidance of President and CEO Harry Zarek who founded the company in 1981, Compugen's experienced team of IT professionals helps mid-sized and large corporations and governments with enterprise-level solutions that address business requirements through an integrated approach across technology platforms. Solution areas include Datacentre, Virtualization, Storage, Microsoft Infrastructure, Print Management, Communications and Security. Service offerings include Deployment, Field (on-site) Services, Managed Services, Technology Lifecycle Management, Fleet Management, Software Licensing and Asset Management. Product Services include a complete ISO warehousing, configuration & logistics organization that encompasses remarketing and recycling of end of life technology. Multi-vendor financing services are provided through Compugen Finance.
Source: Compugen Inc.
Compugen: On the Road to Breakthroughs
http://seekingalpha.com/article/204606-compugen-on-the-road-to-breakthroughs?source=yahoo
Compugen Discovers Drug Target for Treatment of Multiple Myeloma
CGEN-928 demonstrates broad expression in multiple myeloma tumor cells including drug resistant and aggressive primary tumor cell lines
New drug target was predicted in silico through use of Compugen’s Monoclonal Antibody Targets Discovery Platform
Press Release Source: Compugen Ltd. On Tuesday May 11, 2010, 7:00 am EDT
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ%3A+CGEN&index=1&md5=33b176e34bade2fb8fe93d9097f558d3">NASDAQ: CGEN) announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines. In addition, the protein’s expression profile indicates its possible use as both a diagnostic and prognostic marker for multiple myeloma. The potential of CGEN-928 to address these important unmet medical needs was initially predicted through the use of Compugen’s Monoclonal Antibody Targets Discovery Platform. Patent applications covering the use of CGEN-928 for these and additional therapeutic and diagnostic purposes have been filed by the Company.
Dr. James R. Berenson, a leading multiple myeloma specialist and the Medical & Scientific Director of The Institute for Myeloma & Bone Cancer Research in California, where most of this research was conducted, stated, “These early results obtained with CGEN-928 are very encouraging, especially given the fact that this protein is showing high levels of expression in many multiple myeloma tumors that are very drug resistant and highly aggressive.”
Earlier evaluation by Compugen of the in silico predicted CGEN-928 transcript demonstrated high expression levels in multiple myeloma samples compared with various normal tissue samples. Studies were then performed with two independent experimental systems confirming the existence of the CGEN-928 protein on the membranes of cells derived from the bone marrow of multiple myeloma patients, as well as on the membranes of primary tumor cell lines both from cell culture and grown in mice. These experimental results, demonstrating CGEN-928’s broad expression in multiple myeloma tumor cells, support its potential therapeutic value in the treatment of multiple myeloma, including in patients with an aggressive and drug resistant form of the disease. These findings also indicate that CGEN-928 may offer the diagnostic potential to detect a broader population of multiple myeloma cells, including critical drug resistant tumor cells.
Dr. Anat Cohen-Dayag, Compugen’s president and CEO, stated, “We are extremely pleased by our initial portfolio of novel antibody drug targets, such as CGEN-928, which has the potential to meet critical needs for oncology diagnosis and treatment. Due to a number of advantages, antibody therapy is the fastest growing drug class, and identification of appropriate antibody targets is the key discovery challenge. More importantly from a corporate standpoint, Compugen’s recent target candidate discoveries are clearly demonstrating to the biopharmaceutical industry the power and unique capabilities of our Monoclonal Antibody Targets Discovery Platform, and we are now seeing rapidly growing interest in exploring potential collaborations with us in this field.”
7:10AM Compugen announces the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma (CGEN) 4.41 : In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.
Compugen to Host Q&A Conference Call on Wednesday, May 5, 2010 at 10:00 AM EDT
Q&A follows Q1 Corporate Presentation webcast and conference call held on April 27, 2010
Press Release Source: Compugen Ltd. On Monday May 3, 2010, 7:00 am EDT
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ%3A+CGEN&index=1&md5=2b2315e3e485a6f3751fd9447162592a">NASDAQ: CGEN) announced today that the Company will host a live Q&A conference call on Wednesday, May 5, 2010 at 10:00 AM EDT. The Q&A conference call is intended as a follow-up to the Q1 2010 conference call and webcast which took place on April 27, 2010.
During the Q1 2010 conference call, Compugen's chairman, Martin Gerstel, provided a company overview and outlook, including a slide presentation which was, and remains, posted on the Company's website, http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cgen.com&esheet=6273727&lan=en_US&anchor=www.cgen.com&index=2&md5=3aa4ae28f4a6f10a72100339f9bae2de, under the heading "Investors" and subheading "Financial Reports." However, following the slide presentation, the intended Q&A session was not possible due to technical difficulties.
The conference call, scheduled for Wednesday, May 5, 2010, will not involve any presentation by management and will be solely a Q&A session. To access the conference call please dial (toll free) 1-888-407-2553 from the US, or +972-3-918-0644 internationally.
Compugen Reports First Quarter 2010 Financial Results
Corporate Overview and Status to be Presented in Webcast Today at 10 AM EDT
Press Release Source: Compugen Ltd. On Tuesday April 27, 2010, 7:00 am EDT
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ%3A+CGEN&index=1&md5=a6d8e0150157e9130b30007eef5b094f">NASDAQ: CGEN) today reported financial results for the first quarter ending March 31, 2010.
Martin Gerstel, chairman, stated, “Since yearend 2009, we have announced the development of two new discovery platforms, one designed for the prediction and selection of peptide blockers for protein-protein interactions, and the other for cell penetrating peptides. Each of these new platforms provides a significant and broadly applicable capability for systematic therapeutic discovery in a key area where traditional high throughput experimental methodologies have proven largely unsuccessful.”
Mr. Gerstel continued, “These latest achievements continue to demonstrate the value of the unique discovery infrastructure that has been created at Compugen. During the past few years, as a result of successful applications of this infrastructure, we have developed and validated 12 drug and diagnostic discovery platforms, created a growing inventory of product candidates at various stages of validation, and have seen a substantial increase in the recognition of our unique predictive discovery capabilities within the industry. Based on these achievements, we are now substantially increasing our commercialization efforts, focusing primarily on additional product specific agreements and ‘discovery on demand’ collaborations.”
Current revenues, as previously projected, continue to be insignificant with $125,000 for the first quarter of 2010 compared with no revenues for the first quarter of 2009. The net loss for the most recent quarter was $2.7 million (including a non-cash expense of $911,000 related to stock based compensation), or $0.08 per share, compared with a net loss of $2.3 million (including a non-cash expense of $279,000 related to stock based compensation), or $0.08 per share, for the corresponding quarter of 2009.
Research and development expenses of $1.6 million for the first quarter of 2010, compared with $1.4 million for the first quarter of 2009, remain the Company’s largest category of expense. The amount for the first quarter of 2009 is before the deduction of $149,000 of governmental and other grants; no grants were recognized for the first quarter of 2010.
General and administrative expenses for the first quarter of 2010 were $1.0 million, compared with $579,000 for the first quarter of 2009, with the increase due to non-cash expense related to stock based compensation of $609,000 for the first quarter of 2010 compared with $205,000 for the first quarter of 2009.
As of March 31, 2010, Compugen had $22.9 million in cash, cash equivalents and short-term bank deposits, not including the market value of its holding of 1,150,000 Evogene ordinary shares (TASE: EVGN). The Company has no debt.
Conference Call and Webcast Information including Corporate Presentation
The Company will host a live webcast and conference call at 10:00 AM EDT on Tuesday, April 27, 2010 to review first quarter 2010 results and to present a corporate overview and status slide presentation.
The live webcast can be accessed from Compugen’s website (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cgen.com&esheet=6265989&lan=en_US&anchor=www.cgen.com&index=2&md5=95d12e70abd08490504ed3611fa73b8b) or at this link. The presentation slides will be available under corporate presentations on the financial reports page of the investors section of the Compugen website. The audio portion will also be available via conference call, which can be accessed by dialing 1-888-668-9141 from the US, or +972-3-918-0609 internationally.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or 972-3-925-5921 internationally. The replay will be available through April 30, 2010.
Compugen Announces New Drug Discovery Platform to Predict Peptides that Block Protein - Protein Interactions
12th Discovery Platform disclosed by company provides additional broadly applicable capability for “discovery on demand” collaborations
Press Release Source: Compugen Ltd. On Thursday April 22, 2010, 7:00 am EDT
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) announced today the development of its Protein-Protein Interaction Blockers (PPI Blockers) Discovery Platform, designed for the prediction of peptides to block disease associated protein-protein interactions. In a pilot validation run, predicted peptides showed positive results for drug targets in two cancer related pathways of interest to the industry.
The PPI Blockers Discovery Platform consists of two main components. The first component creates a predicted protein-protein interaction map for the protein target of interest in a selected biological pathway. This map is based on both the target’s known protein partners and additional proteins predicted by Compugen as potential partners through the analysis of human and non-human proteomes and interaction data.
The second component, applied to all relevant key proteins of the pathway, is based on identifying computationally the predicted protein-protein binding segments through sequence and structural characteristics. The identification of these segments allows the design and selection of peptides that could serve as drugs by blocking all or a portion of the interacting site. These peptide blockers may either serve as therapeutic peptides or be used as epitopes for the development of therapeutic antibodies. A key advantage of the platform is that it is designed to predict peptides that block a wide range of target proteins and can do so without any knowledge of the three-dimensional structure of the target.
Dr. Zurit Levine, Compugen’s VP R&D, stated, “Both the interaction with another protein (‘protein-protein interaction’) and the formation of a specific conformation through the interaction of separate segments of the same protein (‘intra-molecular interaction’) are required for proteins to exert their function. Therefore blocking one or both of these phenomena as an approach for drug therapy is of intense research worldwide. However, relying on conventional large-scale experimental discovery methods such as screening thousands of compounds or peptides per target has resulted in an extremely low discovery rate of molecules with the required inhibitory effects.”
Dr. Levine continued, “With the development of the PPI Blockers Discovery Platform to predict peptide blockers for protein-protein interaction, and the availability of our previously announced DAC Blockers Platform to predict peptides to block intra-protein binding, Compugen now has the capability to design blocking peptides for both of these key biological phenomena. It is anticipated that this approach will be applicable to a wide range of indications, based on the association of potential target proteins or protein-protein interactions to unmet clinical needs. These two discovery platforms, together with Compugen’s ten other discovery platforms, provide unique and powerful capabilities for enhanced product candidate discovery by Compugen and for potential use in additional 'discovery on demand' collaborations.”
About Protein – Protein Interactions
Protein-protein interactions are central to many key biological functions and thus are attractive targets for a host of diseases. Therefore, the therapeutic applications of inhibiting protein-protein interactions are potentially wide-ranging. However, most efforts so far to discover molecules that modulate protein-protein interactions have been largely unsuccessful, and researchers have long considered them to be “undruggable”.
7:00AM Compugen announces discovery platform to predict cell penetrating peptides for drug delivery (CGEN) 4.97 -0.04 : Co announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.
7:00AM Compugen appoints Dr. Anat Cohen-Dayag as President and CEO Martin Gerstel to reassume Chairman post (CGEN) 4.56 : Co announced the appointment of Anat Cohen-Dayag, Ph.D. as president and CEO, and Martin Gerstel as chairman. Previously, Dr. Cohen-Dayag and Mr. Gerstel served as co-CEOs of the company.
nice announcement and nice move up today! I got in on the dip only to have it dip more so it is nice to see this move to green
7:01AM Compugen discovers novel protein for treatment of autoimmune diseases (CGEN) 3.95 : Co announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders. CGEN-15001 is the extracellular region of a previously unknown membrane protein in the B7/CD28 family. The existence and potential utility of the newly discovered parent protein from which CGEN-15001 is derived was predicted in silico utilizing Compugen's LEADS Platform and other proprietary algorithms.
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
235
|
Created
|
08/22/02
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=CGEN
Compugen Ltd., an early stage drug and diagnostic discovery company, offers therapeutic and diagnostic biomarker product candidates for cancer, cardiovascular, and immune-related diseases in North America and Israel. It develops products using computer-based discovery platforms, as well as through analyzing DNA or RNA sequences, gene expression data, protein network data, data related to drugs in development, and drugs already being commercialized. The company?s validated discovery platforms include Splice Variant based Therapeutic Proteins, Nucleic-Acid Disease Markers, Protein Disease Markers, Monoclonal Antibody Targets, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, GPCR Therapeutic Peptide Ligands, New Indications, Disease-Associated Conformation Blockers, and Viral Peptides Discovery. Its therapeutic product candidates include CGEN-241, a splice variant of the MET receptor; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, the MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; CGEN-25008, a peptide antagonist of the Clusterin protein; CGEN-25009-4, an agonist peptide of the LGR7 receptor; CGEN-54, a splice variant of the MCP-1; CGEN-34, a splice variant of the peptide ANP; and CGEN-50001, a small molecule drug. The company?s diagnostic products include CGEN-144, a variant of the Troponin I biomarker; CGEN-438, a blood based biomarker for lung cancer; CGEN-6, a secreted splice variant protein; and CGEN-327, a biomarker for ovarian cancer. It also develops plant traits to the agbio industry through the use of a platform combining computational genomics, molecular biology, and breeding methods. Compugen has collaboration and license agreements with Roche; Siemens Healthcare Diagnostics, Inc.; Ortho-Clinical Diagnostics; Biosite; Teva Pharmacuetical Industries; Merck & Co.; Medarex, Inc.; and Bayer Schering Pharma AG. The company was founded in 1993 and is based in Tel Aviv, Israel.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |